Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | bromodomain containing 3 | Starlite/ChEMBL | No references |
Homo sapiens | bromodomain containing 4 | Starlite/ChEMBL | No references |
Homo sapiens | bromodomain containing 2 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.016 | 0.3163 | 0.3163 |
Giardia lamblia | Kinase, putative | 0.0115 | 0 | 0.5 |
Onchocerca volvulus | 0.0115 | 0 | 0.5 | |
Entamoeba histolytica | bromodomain-containing protein | 0.0115 | 0 | 0.5 |
Echinococcus granulosus | bromodomain containing 2 | 0.0258 | 1 | 0.5 |
Echinococcus multilocularis | bromodomain containing 2 | 0.0258 | 1 | 1 |
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.0258 | 1 | 1 |
Brugia malayi | Bromodomain containing protein | 0.0258 | 1 | 0.5 |
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.016 | 0.3163 | 0.3163 |
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.016 | 0.3163 | 0.3163 |
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.0258 | 1 | 1 |
Schistosoma mansoni | bromodomain-containing protein 3 brd3 | 0.0258 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0258 | 1 | 1 |
Toxoplasma gondii | bromodomain-containing protein | 0.0115 | 0 | 0.5 |
Entamoeba histolytica | bromodomain-containing protein | 0.0115 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0143 | 0.1964 | 0.1964 |
Trichomonas vaginalis | conserved hypothetical protein | 0.016 | 0.3163 | 0.3163 |
Entamoeba histolytica | bromodomain-containing protein | 0.0115 | 0 | 0.5 |
Trichomonas vaginalis | bromodomain containing protein, putative | 0.016 | 0.3163 | 0.3163 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 18 nM | BindingDB_Patents: TR-FRET In-Vitro Binding Assay. All assays were performed in 384-well microtiter plates. Each assay plate contained 8-point serial dilutions for 40 test compounds, plus 16 high- and 16 low controls. Liquid handling and incubation steps were done on an Innovadyne Nanodrop Express equipped with a robotic arm (Thermo CatX, Perkin Elmer/Caliper Twister II) and an incubator (Liconic STX40, Thermo Cytomat 2C450). The assay plates were prepared by addition of 50 nl per well of compound solution in 90% DMSO HummingBird nanodispenser (Zinsser Analytic). The assay was started by stepwise addition of 4.5 uL per well of bromo domain protein (50 mM HEPES, pH 7.5, 0.005% Tween20, 0.1% BSA, 50 mM NaCl, 45 nM His-Brd2(60-472) or 45 nM His-Brd3(20-477) or 45 nM His-Brd4(44-477) all proteins produced in-house) and 4.5 uL per well of peptide solution (50 mM HEPES, pH 7.5, 0.005% Tween20, 0.1% BSA, 50 mM NaCl, 60 nM acetyl-histone H4 (AcK 5, 8, 12, 16) (Biosyntan GmbH)). Reactions were incubated at 30 C. for 35 minutes. | ChEMBL. | No reference |
IC50 (binding) | > 37000 nM | BindingDB_Patents: AlphaScreen In-Vitro Binding Assay. In order to assess bromodomain selectivity, we set up a binding assay using the bromodomain encoded by the CREBBP gene. Compounds were tested in the CREBBP assay with a similar protocol, however using AlphaScreen (Amplified Luminescent Proximity Homogeneous Assay, Perkin Elmer) as detection readout instead of TR-FRET. The assay was started by stepwise addition of 4.5 uL per well of bromo domain protein (50 mM HEPES, pH 7.5, 0.005% Tween20, 0.02% BSA, 150 mM NaCl, 324 nM His-CREBBP (1081-1197) (custom production at Viva Biotech Ltd.)) and 4.5 uL per well of peptide solution (50 mM HEPES, pH 7.5, 0.005% Tween20, 0.02% BSA, 150 mM NaCl, 120 nM acetyl-histone H4 (AcK 5, 8, 12) (Biosyntan GmbH)). Reactions were incubated at 30 C. for 35 minutes. Subsequently 4.5 uL per well detection mix (50 mM HEPES, pH 7.5, 0.005% Tween20, 0.02% BSA, 150 mM NaCl, 45 ug/ml Ni-chelate acceptor beads, 45 ug/mL streptavidin-donor beads) (Perkin Elmer)) were added. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.